Tenaya Therapeutics (TNYA)
0.39
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form PRE 14A Tenaya Therapeutics, For: Dec 09
October 13, 2026 4:43 PM - SEC Filing
FDA grants RMAT designation to Tenaya's TN-401 heart gene therapy
September 14, 2026 8:32 AM - StreetInsider
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
September 14, 2026 8:30 AM - Globe NewsWire
Form 4 Tenaya Therapeutics, For: Sep 10 Filed by: Ali Faraz
September 11, 2026 8:11 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: Sep 10 Filed by: Tingley Whittemore
September 11, 2026 8:10 PM - SEC Filing
Form SCHEDULE 13G Tenaya Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC
August 24, 2026 5:48 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: Aug 17 Filed by: Ali Faraz
August 17, 2026 8:50 PM - SEC Filing
Form 4 Tenaya Therapeutics, For: Aug 17 Filed by: Tingley Whittemore
August 17, 2026 8:49 PM - SEC Filing
Form 144 Tenaya Therapeutics, Filed by: Ali Faraz
August 17, 2026 8:46 PM - SEC Filing
Form 144 Tenaya Therapeutics, Filed by: Tingley Whittemore
August 17, 2026 8:45 PM - SEC Filing
Tenaya Therapeutics, Inc. (TNYA) Misses Q2 EPS by 14c
August 5, 2026 6:22 PM - StreetInsider
Form S-8 Tenaya Therapeutics,
August 5, 2026 4:28 PM - SEC Filing
Form 10-Q Tenaya Therapeutics, For: Jun 30
August 5, 2026 4:19 PM - SEC Filing
Form 8-K Tenaya Therapeutics, For: Aug 05
August 5, 2026 4:14 PM - SEC Filing
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026 4:05 PM - Globe NewsWire
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026 4:05 PM - Globe NewsWire
Full Article List
